Literature DB >> 20204314

[Sialadenitis and sialolithiasis].

H Maier1.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20204314     DOI： 10.1007/s00106-009-2073-2

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


× No keyword cloud information.
  7 in total

1.  Sialendoscopy-based diagnosis and classification of parotid duct stenoses.

Authors:  Michael Koch; Heinrich Iro; Johannes Zenk
Journal:  Laryngoscope       Date:  2009-09       Impact factor: 3.325

2.  Health-related quality of life, employment and disability in patients with Sjogren's syndrome.

Authors:  Jiska M Meijer; Petra M Meiners; James J R Huddleston Slater; Fred K L Spijkervet; Cees G M Kallenberg; Arjan Vissink; Hendrika Bootsma
Journal:  Rheumatology (Oxford)       Date:  2009-06-24       Impact factor: 7.580

Review 3.  Diagnosis of major salivary gland tuberculosis: experience of eight cases and review of the literature.

Authors:  Young Ho Kim; Woo-Jin Jeong; Kwang-Yoon Jung; Myung-Whun Sung; Kwang Hyun Kim; Chong Sun Kim
Journal:  Acta Otolaryngol       Date:  2005-12       Impact factor: 1.494

Review 4.  The bacteriology of salivary gland infections.

Authors:  Itzhak Brook
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2009-08       Impact factor: 2.802

5.  Outcome of minimally invasive management of salivary calculi in 4,691 patients.

Authors:  Heinrich Iro; Johannes Zenk; Michael P Escudier; Oded Nahlieli; Pasquale Capaccio; Philippe Katz; Jackie Brown; Mark McGurk
Journal:  Laryngoscope       Date:  2009-02       Impact factor: 3.325

6.  Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.

Authors:  Serge D Steinfeld; Laure Tant; Gerd R Burmester; Nick K W Teoh; William A Wegener; David M Goldenberg; Olivier Pradier
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 7.  The future of biologic agents in the treatment of Sjögren's syndrome.

Authors:  Jiska M Meijer; Justin Pijpe; Hendrika Bootsma; Arjan Vissink; Cees G M Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.